Ekso Bionics (NASDAQ:EKSO) Price Target Lowered to $9.00 at HC Wainwright

Ekso Bionics (NASDAQ:EKSO) had its price objective lowered by HC Wainwright from $10.00 to $9.00 in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Ekso Bionics’ Q4 2024 earnings at ($0.06) EPS, FY2024 earnings at ($0.48) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.02) EPS, FY2026 earnings at $0.02 EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.43 EPS.

Separately, StockNews.com assumed coverage on shares of Ekso Bionics in a report on Saturday, October 26th. They issued a “hold” rating on the stock.

Ekso Bionics Stock Down 8.2 %

EKSO opened at $0.86 on Tuesday. Ekso Bionics has a 52 week low of $0.83 and a 52 week high of $3.13. The business has a 50 day moving average price of $1.11 and a two-hundred day moving average price of $1.15. The company has a quick ratio of 1.77, a current ratio of 2.81 and a debt-to-equity ratio of 0.28.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $6.00 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. During the same period in the prior year, the business earned ($0.24) earnings per share. On average, equities research analysts predict that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC raised its holdings in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the period. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. 6.42% of the stock is currently owned by institutional investors and hedge funds.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.